Furthermore, first-line treatment of HER2-positive breast cancers with trastuzumab presents response rates that vary between 25% and 35%, and the benefit of trastuzumab therapy has been shown only in patients with high levels of HER2 amplification [4]. The gene discussed is ERBB2; the disease is breast carcinoma.